In thyroid cancer, alongside metabolic reprogramming, EMT is also characterized by alterations in integrin expression and modifications in the interactions between integrins and the ECM, particularly FN (Fedele et al. 2022), a key ECM glycoprotein that has been proposed to play an important role in cancer. This evidence concerns the gene FN1 and thyroid gland carcinoma.